Abstract: Compositions comprising Tr1 cells directed to a multiple sclerosis associated antigen and methods for treating multiple sclerosis.

Abstract: Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition.

Abstract: Compositions including human Treg cells directed to an eye-associated antigen and methods for treating uveitis.

Abstract: A method for assessing whether a patient subjected to an antigen-specific Tr1 cell therapy is responding to the treatment, includes: determining in vitro the antigen-specific proliferation of T cells contained in a cell sample from the patient; and comparing the antigen-specific proliferation to a standard reference, thereby determining whether the patient is responding or not to the treatment.

Abstract: A method for the in vitro production of a cell population P? from a cell population P, the production requiring the presence of at least one factor which is expressed by feeder cells, wherein a) feeder cells proliferate at a temperature T1, b) proliferated feeder cells are contacted with the cell population P, c) the cell mixture obtained at step (b) is cultivated at a temperature T2 which is chosen such that the cell population P proliferates and the feeder cells do not proliferate, the at least one factor being expressed by the feeder cells, and d) the cell population P? so produced is recovered. Advantageously, the production consists in an expansion, the feeder cells are insect feeder cells and the cell population P to be expanded is a T lymphocyte population, preferably a Trl lymphocyte population.

Abstract: A method of regulatory cell therapy for a treating a patient in need thereof, wherein 104 to 106 regulatory T cells are administrated to the patient.

Abstract: A method for assessing whether a patient subjected to an antigen-specific Tr1 cell therapy is responding to the treatment, includes: determining in vitro the antigen-specific proliferation of T cells contained in a cell sample from the patient; and comparing the antigen-specific proliferation to a standard reference, thereby determining whether the patient is responding or not to the treatment.

Abstract: The present invention relates to an isolated Tr1-like cell population capable of producing IL-13, the population having immunosuppressive activities; methods for identifying/isolating/enriching the population and its uses thereof.

Abstract: The present invention relates to methods for isolating Tr1 cells, resting Tr1 cells and/or activated Tr1 cells, to methods for enriching or depleting a cell population in Tr1 cells, resting Tr1 cells and/or activated Tr1 cells and to methods and kits for treating chronic inflammatory diseases, autoimmune diseases, allergic diseases, cancer and organ transplantation conditions.

Abstract: Compositions including human Tr1 cells directed to an allergen associated to an allergen or asthmatic provided the allergen is not a food allergen and use thereof for treating an allergic or asthmatic condition, excluding a food allergic condition.

Abstract: The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.

Abstract: An in vitro method for the obtention of a food- or auto-antigen specific Tr1 cell population from a leukocyte or a PBMC population, includes stimulating the PBMC or leukocyte population with the food- or auto-antigen, and recovering the food- or auto-antigen specific Tr1 cell population from the stimulated cell population. Preferably, the PBMC or leukocyte population is re-stimulated at least once with the same antigen after step (1), in the presence of IL-2 and at least one interleukin selected from the group consisting of IL-4 and IL-13. The in vitro method may further include a third step of expanding the recovered antigen-specific Tr1 cell population, advantageously by contacting them with feeder cells capable of expressing factors necessary for the expansion. Preferably, the feeder cells are recombinant insect feeder cells.

Abstract: The present invention relates to a medicament comprising human Tr1 cells directed to a human HSP and methods for treating an inflammatory autoimmune condition.

Abstract: The present invention relates to compositions comprising human Tr1 cells directed to a joint-associated antigen and methods for treating an arthritic condition.

Abstract: Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition.

Abstract: The present invention relates to compositions comprising Tr1 cells and mesenchymal stem cells and methods for treating an autoimmune disease, an allergic disease or an inflammatory disease.

Abstract: Compositions comprising Tr1 cells directed to a multiple sclerosis associated antigen and methods for treating multiple sclerosis.

Abstract: The invention relates to a method for identification of Tr1 lymphocyte regulators in a biological sample, based on the determination of the simultaneous presence of the molecular group CD4, CD18 and/or CD11a, CD49b and, where appropriate, by the demonstration of an over-expression of genes coding for the molecules CD4, PSGL-1, PECAM-1 and alphaV/beta3. The invention further relates to a method of quantification and a prognostic or diagnostic method for auto-immune or inflammatory diseases, based on said identification method. The invention also relates to an enrichment method for Tr1 lymphocyte regulators, based on the determination of the simultaneous presence of said molecules and, finally, an enriched composition from said enrichment method, for the treatment of an auto-immune or inflammatory disease, in particular Crohn's disease.

Abstract: The present invention relates to compositions comprising Tr1 cells directed to a multiple sclerosis associated antigen and methods for treating multiple sclerosis.

Abstract: The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.